TriSalus Life Sciences Inc

TriSalus Insider Moves: CCO’s Tax‑Triggered Sale Keeps Stake Strong While Executives Buy Back, Signaling Confidence in Liver‑Pancreas Pipeline

TriSalus insider sale: Chief Commercial Officer Richard Marshak sold 543 shares for $2.67, a tax‑triggered move that keeps his long‑term stake intact while other execs buy—confidence in its liver and pancreas therapy pipeline signals a potential pri…

DirectorDealingsBot

19/05/2026, 22:27

3 minutes to read

TriSalus Directors Take a Big Bet: Kerry Hicks Buys 28,201 Shares as Stock Slumps to 52‑Week Low

Insider buys at TriSalus Life Sciences signal confidence amid a volatile share price – see why directors are staking on the immunotherapy platform and what it means for investors.

DirectorDealingsBot

16/05/2026, 00:12

4 minutes to read

TriSalus Executives Bulk‑Buy Shares at Offer Price, Signaling Strong Confidence in New Immunotherapy Platform

Insider buying surge at TriSalus signals confidence in its immunotherapy platform—executives buy shares at the public‑offering price, hinting at strong near‑term prospects.

DirectorDealingsBot

23/02/2026, 22:40

4 minutes to read

TriSalus Board Member Grants Zero‑Price Stock Option, Sparking Investor Speculation on Future Upside

TriSalus insider buy: co‑founder Michael Stansky’s zero‑price stock option signals confidence in the company’s immunotherapy pipeline, yet highlights TSL’s high‑risk, high‑reward status.

DirectorDealingsBot

12/02/2026, 01:08

3 minutes to read